Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QTTB
stocks logo

QTTB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast QTTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTTB is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast QTTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTTB is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.620
sliders
Low
10.00
Averages
15.00
High
20.00
Current: 3.620
sliders
Low
10.00
Averages
15.00
High
20.00
Wells Fargo
Derek Archila
Hold
Maintains
$16 → $15
2025-03-12
Reason
Wells Fargo
Derek Archila
Price Target
$16 → $15
2025-03-12
Maintains
Hold
Reason
Piper Sandler
Christopher Raymond
Buy
to
Hold
Downgrades
$20 → $4
2025-02-11
Reason
Piper Sandler
Christopher Raymond
Price Target
$20 → $4
2025-02-11
Downgrades
Buy
to
Hold
Reason
Piper Sandler downgraded Q32 Bio to Neutral from Overweight with a price target of $4, down from $20. The firm is surprised by the company's decision to discontinue complement inhibitor ADX-097 before presenting data from the drug's renal basket study. The best course of action is to move to Neutral on the name until a better picture of bempikibart's efficacy profile in alopecia areata emerges, the analyst tells investors in a research note.
BMO Capital
Etzer Darout
Buy
to
Hold
Downgrades
$22 → $3
2025-02-11
Reason
BMO Capital
Etzer Darout
Price Target
$22 → $3
2025-02-11
Downgrades
Buy
to
Hold
Reason
BMO Capital downgraded Q32 Bio to Market Perform from Outperform with a price target of $3, down from $22. The company announced an internal restructuring, discontinuing development of its main value driver, ADX-097, to focus on bempikibart development in patients with alopecia areata, the analyst tells investors in a research note. The firm says that while te decision seems to signal confidence in bempikibart, the drug's early clinical profile is not compelling enough to merit meaningful value beyond what it already assumes. As such, it removed contributions from ADX-097 and downgraded the shares.
BMO Capital
Etzer Darout
Buy
Maintains
$64 → $22
2024-12-12
Reason
BMO Capital
Etzer Darout
Price Target
$64 → $22
2024-12-12
Maintains
Buy
Reason
Guggenheim
Yatin Suneja
Strong Buy
to
Hold
Downgrades
n/a
2024-12-12
Reason
Guggenheim
Yatin Suneja
Price Target
n/a
2024-12-12
Downgrades
Strong Buy
to
Hold
Reason
Piper Sandler
Christopher Raymond
Buy
Maintains
$85 → $20
2024-12-11
Reason
Piper Sandler
Christopher Raymond
Price Target
$85 → $20
2024-12-11
Maintains
Buy
Reason
Piper Sandler analyst Christopher Raymond lowered the firm's price target on Q32 Bio to $20 from $85 and keeps an Overweight rating on the shares following messy Phase 2a readouts for bempikibart in both atopic dermatitis and alopecia areata. In Part B of the SIGNAL-AD trial, there was no difference between treatment and placebo on EASI score reduction due to an abnormally high placebo rate, and Q32 Bio is halting all further development activities in this indication. For AA, efficacy data were underwhelming compared to approved JAKi's, and although the company has a plan to try and boost efficacy, Piper thinks the risk here is high and is taking this out of its model for now. This leaves differentiated complement inhibitor ADX-097 as the sole value driver in our model, and the firm looks to preliminary data from the Phase 2 renal basket trial in the first half of 2025 to establish the future value of this name.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Q32 Bio Inc (QTTB.O) is -0.51, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Q32 Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.29
Current PE
-0.51
Overvalued PE
-0.92
Undervalued PE
-7.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 242.3% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 242.3% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

QTTB News & Events

Events Timeline

(ET)
2025-12-01
07:18:00
Q32 Bio (QTTB) Sells ADX-097 to Akebia Therapeutics for $12M
select
2025-12-01
07:17:00
Akebia Acquires Rare Kidney Drug AKB-097 for $7M
select
2025-11-13 (ET)
2025-11-13
07:00:44
Q32 Bio Announces Q3 EPS of 60 Cents, Below Consensus Estimate of $1.19
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02NASDAQ.COM
Q32 Bio Transfers ADX-097, a Complement Inhibitor, to Akebia Therapeutics

  • Q32 Bio's Sale of ADX-097: Q32 Bio Inc. has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront and potential future payments totaling up to $592 million, extending its cash runway into 2027.

  • Focus on Bempikibart: Following the sale, Q32 Bio is concentrating on its flagship program, bempikibart (ADX-914), which is in Phase 2 development for alopecia areata, with results expected in mid-2026.

  • Retained Rights and Future Plans: Q32 Bio retains rights to its tissue-targeted complement inhibitor platform, including ADX-096, and is exploring strategic options for these programs while advancing bempikibart.

  • Stock Performance: QTTB's stock experienced a significant increase of 74.43% before slightly declining, with trading volume surging to about 16.6 million shares, indicating heightened investor interest.

[object Object]
Preview
4.5
12-02Benzinga
Crude Oil Rises More Than 1%; November Sees Decline in ISM Manufacturing PMI

  • U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling approximately 250 points, while the S&P 500 and NASDAQ also experienced losses. Energy shares rose by 1%, but utilities stocks dropped by 2.1%.

  • Manufacturing PMI Data: The ISM manufacturing PMI fell to 48.2 in November, marking the lowest reading in four months and missing market expectations, while the S&P Global manufacturing PMI was revised slightly higher to 52.2.

  • Notable Stock Movements: Q32 Bio Inc. shares surged 103% after a significant sale, while New Fortress Energy Inc. and KALA Bio, Inc. also saw substantial gains. Conversely, Sionna Therapeutics, Inc. and CN Energy Group Inc. experienced notable declines.

  • Global Market Trends: European shares mostly fell, with the eurozone's STOXX 600 down 0.20%, while Asian markets closed mixed, with Japan's Nikkei dropping 1.89% and Hong Kong's Hang Seng gaining 0.67%.

[object Object]
Preview
4.5
12-01Benzinga
Dow Falls 200 Points; Q32 Bio Stock Soars

  • Market Performance: U.S. stocks opened lower, with the Dow Jones down approximately 200 points, while the NASDAQ and S&P 500 also experienced declines of 1.08% and 0.68%, respectively.

  • Sector Movements: Energy shares rose by 1%, while communication services stocks fell by 1.2%.

  • Equities Highlights: Q32 Bio Inc. saw a significant increase of 171% after a major sale, while Paranovus Entertainment Technology Ltd. experienced a sharp decline of 81%.

  • Global Market Trends: European shares mostly fell, with the eurozone's STOXX 600 down 0.4%, and Asian markets closed mixed, highlighted by Japan's Nikkei dropping 1.89%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Q32 Bio Inc (QTTB) stock price today?

The current price of QTTB is 3.62 USD — it has increased 1.4 % in the last trading day.

arrow icon

What is Q32 Bio Inc (QTTB)'s business?

Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.

arrow icon

What is the price predicton of QTTB Stock?

Wall Street analysts forecast QTTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTTB is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Q32 Bio Inc (QTTB)'s revenue for the last quarter?

Q32 Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Q32 Bio Inc (QTTB)'s earnings per share (EPS) for the last quarter?

Q32 Bio Inc. EPS for the last quarter amounts to -0.90 USD, decreased -85.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Q32 Bio Inc (QTTB)'s fundamentals?

The market is revising No Change the revenue expectations for QTTB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 116.77%.
arrow icon

How many employees does Q32 Bio Inc (QTTB). have?

Q32 Bio Inc (QTTB) has 42 emplpoyees as of December 05 2025.

arrow icon

What is Q32 Bio Inc (QTTB) market cap?

Today QTTB has the market capitalization of 0.00 USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free